2215-CL-0304

2215-CL-0304

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML 


Study Treatments


Inclusion criteria


Exclusion criteria


Participating sites

Link